Amylyx Pharmaceuticals Inc. is likely to see its first U.S. drug approval following an unusual second meeting of expert advisers to the Food and Drug Administration. But even once it is approved, the FDA left open the option to pull the drug from the market if it fails in a confirmatory study.
